NetrinG1 Biomarker Detection in Desmoplastic Stroma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pancreatic ductal adenocarcinoma (PDAC) is characterized by desmoplasia, a fibrous microenvironment that is hypo-angiogenic and immunosuppressive, making it challenging to treat effectively, with current therapies having abysmal 5-year survival rates due to the stroma's ability to metabolically support tumor cells and suppress immune activity.
Innovation Solution
Detecting increased levels of NetrinG1 (NetG1) and its binding partner NGL1 in desmoplastic stroma or circulating extracellular vesicles, and administering interferon gamma to prime immune cells, followed by immune checkpoint inhibitors to revert desmoplastic stroma to a normal phenotype, thereby reducing immunosuppressive cytokines and enhancing anti-tumor immune activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If desmoplastic stroma is present in PDAC, then tumor cells receive metabolic support and immune suppression is enhanced, but treatment efficacy is significantly reduced
Solution Approach 1:
The patent extracts and removes the harmful desmoplastic stroma component from the tumor microenvironment through desmoplastic ablation therapy. By selectively eliminating the fibrotic stromal tissue that provides metabolic support and immune suppression, the treatment removes the protective barrier around tumor cells, thereby enhancing the effectiveness of subsequent anti-tumor therapies without directly attacking the tumor cells themselves
Solution Approach 2:
The patent changes the physical and biological parameters of the desmoplastic stroma by applying ablation energy (thermal, mechanical, or chemical) to alter its structure and function. This parameter change transforms the stroma from a protective, immunosuppressive state to a disrupted state that no longer supports tumor metabolism or suppresses immune activity, thereby improving treatment response
2Object-generated harmful factors
If desmoplastic ablation is performed, then stromal support for tumor cells is reduced, but patient outcomes are detrimental
Solution Approach 1:
The patent applies desmoplastic ablation as a preliminary action before administering anti-tumor therapy. By first disrupting the desmoplastic stroma, the treatment creates a more favorable microenvironment for subsequent immunotherapy or chemotherapy to work effectively. This sequential approach addresses the stromal barrier first, then exploits the resulting vulnerability of tumor cells to treatment
Solution Approach 2:
The patent uses desmoplastic ablation as an intermediary step that mediates between the tumor cells and the immune system. By selectively removing the immunosuppressive stroma without directly killing tumor cells, the treatment facilitates enhanced immune recognition and attack on tumor cells, thereby improving overall patient outcomes through this intermediate therapeutic action
3Reliability
If NetG1/NGL1 engagement occurs between CAFs and PDAC cells, then PDAC cells gain survival advantages and are protected from NK cell elimination, but tumor growth is enhanced
Solution Approach 1:
The patent extracts and blocks the NetG1/NGL1 interaction interface between CAFs and PDAC cells using neutralizing antibodies or small molecule inhibitors. By specifically targeting this cell-cell communication pathway, the treatment removes the protective signaling that allows tumor cells to survive nutrient deprivation and evade NK cell-mediated immunity, thereby enhancing anti-tumor immune activity without affecting normal tissue function
Solution Approach 2:
The patent uses NetG1 or NGL1 proteins as biomarkers to detect and monitor the presence and activity of the protective cell-cell interaction. By measuring levels of these proteins in patient samples, the treatment enables non-invasive monitoring of desmoplastic activity and prediction of treatment response, allowing for personalized therapy adjustment based on individual patient tumor microenvironment characteristics
Data Source
AI summary
The present disclosure provides methods of inducing desmoplastic stroma to express a normal phenotype by detecting increased levels of NetG1 or NGL1 in tumor or in desmoplastic stroma isolated from a human subject, and/or detecting NetG1 in circulating extracellular vesicles, and/or detecting increased pFAK in the stroma, and treating the human subject with a therapeutic regimen; and by detecting NetG1 in a microvesicle isolated from a human subject, and/or treating the human subject with a therapeutic regimen.